Clinical Trial Update: Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS) [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating 1 mg Osilodrostat for Mild Autonomous Cortisol Secretion (MACS) and Autonomous Cortisol Secretion (ACS), and is currently recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autonomous Cortisol Secretion

Drugs mentioned

• Osilodrostat (Isturisa) (osilodrostat)

Snippet

Sponsor: Mayo Clinic | Conditions: Mild Autonomous Cortisol Secretion, Autonomous Cortisol Secretion (ACS) | Phase 2 | Status: RECRUITING